Clinical Trial Update: Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections [Phase 3]

View source ↗

Summary

Phase 3 trial comparing oral sodium fusidate (CEM-102) to oral linezolid for acute bacterial skin and skin structure infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infections

Drugs mentioned

• CEM-102 (oral sodium fusidate) (sodium fusidate)
• Linezolid (Linezolid)

Snippet

Sponsor: Arrevus Inc. | Conditions: Acute Bacterial Skin and Skin Structure Infections | Phase 3 | Status: COMPLETED